MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 3.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,466 shares of the life sciences company’s stock after buying an additional 1,437 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Integra LifeSciences were worth $872,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of IART. Capital Research Global Investors grew its stake in shares of Integra LifeSciences by 7.4% during the 4th quarter. Capital Research Global Investors now owns 1,400,559 shares of the life sciences company’s stock valued at $31,765,000 after acquiring an additional 95,944 shares during the period. Lord Abbett & CO. LLC boosted its position in shares of Integra LifeSciences by 86.8% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company’s stock worth $30,210,000 after purchasing an additional 618,773 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Integra LifeSciences by 10.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,047,573 shares of the life sciences company’s stock worth $23,759,000 after purchasing an additional 103,291 shares during the period. Northern Trust Corp increased its stake in shares of Integra LifeSciences by 9.9% in the fourth quarter. Northern Trust Corp now owns 892,425 shares of the life sciences company’s stock worth $20,240,000 after purchasing an additional 80,090 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of Integra LifeSciences by 5.5% during the 4th quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company’s stock valued at $9,603,000 after purchasing an additional 22,000 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $12.30 on Tuesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a 1-year low of $11.60 and a 1-year high of $32.66. The business has a 50 day simple moving average of $16.82 and a two-hundred day simple moving average of $21.22. The stock has a market capitalization of $955.86 million, a PE ratio of -136.65, a P/E/G ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.02). The business had revenue of $382.65 million during the quarter, compared to analysts’ expectations of $381.17 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period last year, the business posted $0.55 earnings per share. On average, research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Truist Financial cut their price target on Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a research note on Friday, April 11th. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, March 31st. JPMorgan Chase & Co. lowered their price target on Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating on the stock in a report on Tuesday, May 6th. JMP Securities dropped their price target on Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating for the company in a research note on Friday, May 9th. Finally, Wells Fargo & Company reduced their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 6th. Four investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $18.63.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.